» Articles » PMID: 12768034

Mutagenesis Versus Inhibition in the Efficiency of Extinction of Foot-and-mouth Disease Virus

Overview
Journal J Virol
Date 2003 May 28
PMID 12768034
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

RNA viruses replicate near the error threshold for maintenance of genetic information, and an increase in mutation frequency during replication may drive RNA viruses to extinction in a process termed lethal mutagenesis. This report addresses the efficiency of extinction (versus escape from extinction) of foot-and-mouth disease virus (FMDV) by combinations of the mutagenic base analog 5-fluorouracil (FU) and the antiviral inhibitors guanidine hydrochloride (G) and heparin (H). Selection of G- or H-resistant, extinction-escape mutants occurred with low-fitness virus only in the absence of FU and with high-fitness virus with some mutagen-inhibitor combinations tested. The combination of FU, G, and H prevented selection of extinction-escape mutants in all cases examined, and extinction of high-fitness FMDV could not be achieved by equivalent inhibitory activity exerted by the nonmutagenic agents. The G-resistant phenotype was mapped in nonstructural protein 2C by introducing the relevant mutations in infectious cDNA clones. Decreases in FMDV infectivity were accompanied by modest decreases in the intracellular and extracellular levels of FMDV RNA, maximal intracellular concentrations of FU triphosphate, and a decrease in the intracellular concentrations of UTP. In addition to indicating a key participation of mutagenesis in virus extinction, the results suggest that picornaviruses provide versatile experimental systems to approach the problem of extinction failure associated with inhibitor-escape mutants during treatments based on enhanced mutagenesis.

Citing Articles

Genetic and phenotypic changes to Venezuelan equine encephalitis virus following treatment with β-D-N4-hydroxycytidine, an RNA mutagen.

Alejandro B, Kim E, Hwang J, Park J, Smith M, Chung D Sci Rep. 2024; 14(1):25265.

PMID: 39448734 PMC: 11502654. DOI: 10.1038/s41598-024-76788-x.


The multiple roles of viral 3D protein in picornavirus infections.

Nie Z, Zhai F, Zhang H, Zheng H, Pei J Virulence. 2024; 15(1):2333562.

PMID: 38622757 PMC: 11020597. DOI: 10.1080/21505594.2024.2333562.


Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity.

Hadj Hassine I, Mhadheb M, Menendez-Arias L Viruses. 2022; 14(4).

PMID: 35458571 PMC: 9024455. DOI: 10.3390/v14040841.


Adaptive value of foot-and-mouth disease virus capsid substitutions with opposite effects on particle acid stability.

Caridi F, Canas-Arranz R, Vazquez-Calvo A, de Leon P, Calderon K, Domingo E Sci Rep. 2021; 11(1):23494.

PMID: 34873184 PMC: 8648728. DOI: 10.1038/s41598-021-02757-3.


Synthesis, Antitumor and Antiviral Activities of New Benzotriazole-Dicarboxamide Derivatives.

Ibba R, Piras S, Corona P, Riu F, Loddo R, Delogu I Front Chem. 2021; 9:660424.

PMID: 34017818 PMC: 8129498. DOI: 10.3389/fchem.2021.660424.


References
1.
Saunders K, King A . Guanidine-resistant mutants of aphthovirus induce the synthesis of an altered nonstructural polypeptide, P34. J Virol. 1982; 42(2):389-94. PMC: 256864. DOI: 10.1128/JVI.42.2.389-394.1982. View

2.
Toja M, Escarmis C, Domingo E . Genomic nucleotide sequence of a foot-and-mouth disease virus clone and its persistent derivatives. Implications for the evolution of viral quasispecies during a persistent infection. Virus Res. 1999; 64(2):161-71. DOI: 10.1016/s0168-1702(99)00089-1. View

3.
Sobrino F, Davila M, Ortin J, Domingo E . Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture. Virology. 1983; 128(2):310-8. DOI: 10.1016/0042-6822(83)90258-1. View

4.
Bartal S, TERSHAK D . Guanidine-resistant poliovirus mutants produce modified 37-kilodalton proteins. J Virol. 1984; 50(3):922-8. PMC: 255754. DOI: 10.1128/JVI.50.3.922-928.1984. View

5.
Eastman P, Blair C . Temperature-sensitive mutants of Japanese encephalitis virus. J Virol. 1985; 55(3):611-6. PMC: 255022. DOI: 10.1128/JVI.55.3.611-616.1985. View